ENLIVEN THERAPEUTICS, INC. (ELVN)

SEC filing

ENLIVEN THERAPEUTICS, INC.

ELVN · CIK 1672619

4 · Sep 21, 2026 · CHIEF FINANCIAL OFFICER Hohl Benjamin sold 6,018 shares at $50.35/share ($303.0K); exercised options for 7,964 shares

CHIEF FINANCIAL OFFICER Hohl Benjamin sold 6,018 shares at $50.35/share ($303.0K); exercised options for 7,964 shares

xslF345X06/form4-09212026_090936.xml

xslF345X06/form4-09212026_090936.xmlSEC.gov

Graphics and non-inline formats (not embedded below).